Merus N.V.

Company Listings from SPi: Merus N.V.

You are here: Home >> SPi Company Listings >> Merus N.V.

 

Merus N.V.

Website:
http://

Search for other references to "merus" on SPi News

Latest Merus N.V. News

Merus to Present at the Jefferies 2018 London Healthcare Conference UTRECHT, The Netherlands, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeut...... 12:00 GMT Thursday 8th November 2018

Merus to Present at the Cantor Fitzgerald Global Healthcare Conference UTRECHT, The Netherlands, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeu...... 21:00 GMT Thursday 27th September 2018

Merus Strengthens Team with Key Appointments Hui Liu, Ph.D., EVP, Chief Business Officer, appointed Head of Merus U.S.Peter B. Silverman, J.D., appointed EVP, General CounselJillian Connell joins as VP, Investor Relations and...... 12:00 GMT Thursday 27th September 2018

Merus to Participate in Citi’s 13th Annual Biotech Conference UTRECHT, The Netherlands, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeut...... 12:00 GMT Thursday 30th August 2018

Merus Announces Formation of a Scientific Advisory Board UTRECHT, The Netherlands, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeut...... 12:00 GMT Wednesday 22nd August 2018

Merus Announces Financial Results for the Second Quarter 2018 & Mid-year Operating Results UTRECHT, The Netherlands, Aug. 10, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology com...... 13:35 GMT Friday 10th August 2018

Merus to Present at the 2018 Wedbush PacGrow Healthcare Conference UTRECHT, The Netherlands, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeut...... 12:00 GMT Tuesday 7th August 2018

Merus N.V. : Merus Announces Recent Corporate Developments and Financial Results for the First Quarter 2018 - Initiation of Phase 1, first-in-human clinical trial of MCLA-158 in patients with solid tumors - - MCLA-128's unique mechanism of action published in the scientific journal...... 12:00 GMT Thursday 26th July 2018

Merus Announces Recent Corporate Developments and Financial Results for the First Quarter 2018 UTRECHT, The Netherlands, July 26, 2018 (GLOBE NEWSWIRE) --  Merus N.V. (Nasdaq:MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology c...... 12:00 GMT Thursday 26th July 2018

Merus Announces Annual Meeting of Shareholders UTRECHT, The Netherlands, July 05, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody thera...... 09:00 GMT Thursday 5th July 2018

Buy Merus N.V.
Market Reports
from SPi

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us